A Phase 1 clinical trial evaluating dulaglutide (LY2189265) reached completed status as of August 21, 2026. The study, registered as NCT07313813, examined the effect of fasting duration and dulaglutide withholding on gastric retention in participants with type 2 diabetes mellitus.
According to the trial record, this was a Phase 1 study. The listed status for the trial is completed. No results, efficacy outcomes, or safety findings were included in this update. The event data reports only the study title, phase, and completion status as of the stated date.
Dulaglutide is an approved compound, and this trial specifically focused on gastric retention in the context of fasting duration and medication withholding among people with type 2 diabetes mellitus. Further details about study outcomes are not part of this update and would require review of the full trial record.
Readers interested in background on dulaglutide can consult the compound overview for additional context.